Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
A phase 3 trial of Adagloxad simolenin run by OBI Pharma, Inc, active.
Overview
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC is a phase 3 interventional study registered as NCT03562637 by OBI Pharma, Inc, with 575 participants enrolled, started 2018-12-05. Conditions listed: Triple Negative Breast Cancer. No results are recorded here; the registry entry is the source.
Setting
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer
Phase
Phase 3
Sponsor
OBI Pharma, Inc
Registry
Enrolled
575